Idiopathic environmental intolerances (IEI): From molecular epidemiology to molecular medicine

Indian Journal of Experimental Biology

Volumn 48, Issue 7, 2010, Pages 625-635

  de Luca, C ^a   Scordo, G ^b   Cesareo, E ^a   Raskovic, D ^a   Genovesi, G ^c   Korkina, L ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antioxidants; Chelators; Genetic polymorphism; Idiopathic environmental intolerances; Redox imbalance

Indexed keywords

HUMAN; MOLECULAR EPIDEMIOLOGY; MULTIPLE CHEMICAL SENSITIVITY; REVIEW;

HUMANS; MOLECULAR EPIDEMIOLOGY; MULTIPLE CHEMICAL SENSITIVITY;

EID: 77954264029     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Winder C, Mechanism of multiple chemical sensitivity, ToxicolLett, 128 (2002) 85.
2. Bornschein S, Förstl H & Zilker T, Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives, J Intern Med, 250 (2001) 309.
3. International Programme on Chemical Safety/World Helath Organization (IPCSAVHO).Conclusion and recommendations of a wokshop on multiple chemical sensitivities (MCS), Regu Toxicol Pharmacol, 24 (1996) S79.
4. Wiesmüller G A, Ebel H, Hornberg C, Kwan O & Friel J, Are syndromes in environmental medicine variants of somatoform disorders? Med Hypotheses, 61 (2003) 419.
5. Kipen H M & Fiedler N, Environmental factors in medically unexplained symptoms and related syndromes: The evidence and the challenge, Environ Health Perspect, 110 Suppl. (2002) 597.
6. Karlson E W, Watts J, Singorovitch J, Bonetti M, Wright E & Cooper G S, Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: Results from the Roxbury lupus project, Arthritis Rheum, 56 (2007) 244.
7. Yun B R, El-Sohemy A, Cornells M C & Bae S C, Glutathione S-transferase Ml, Tl, and PI genotypes and rheumatoid arthritis, J Rheumatol, 32 (2005) 992.
8. Bolt H M & Kiesswetter E, Is multiple chemical sensitivity a clinically defined entity? Toxicol Lett, 128 (2002) 99.
9. Bornschein S, Förstl H & Zilker T, Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives, J Intern Med, 250 (2001) 309.
10. Mayou R, Somatization, Psycother Psychom, 59 (1993) 69.
11. Waickman F J & Vojdani A, Putting chemical and environmental sensitivities in perspective. Otolaryngol Clin North Am, 31(1998) 55.
12. Yadav S, Zajac E, Singhal S S & Awasthi S, Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters. Cancer Metastasis Rev, 26 (2007) 59.
13. Mattson M P & Cheng A, Neurohormetic phytochemicals: Low-dose toxins that induce adaptive neuronal stress responses, Trends Neurosci, 29 (2006) 632.
14. Greene G J & Kipen H M, The vomeronasal organ and chemical sensitivity: A hypothesis, Environ Health Perspect, 110 Suppl 4 (2002) 655.
15. Cullen M R, The worker with multiple chemical sensitivities: An overview, Occup Med, 2 (1987) 655.
16. Miller C S & Prihoda T J, A controlled comparison of symptoms and chemical intolerances reported by Gulf War veterans, implant recipients and persons with multiple chemical sensitivity, Toxicol Ind Health, 15 (1999) 386.
17. Bailer J, Witthöft M, Paul C, Bayerl C & Rist F, Evidence for overlap between idiopathic environmental intolerance and somatoform disorders. Psychosom Med, 67 (2005) 921.
18. Bornschein S, Hausteiner C, Römmelt H, Nowak D, Förstl H & Zilker T, Double-blind placebo-controlled provocation study in patients with subjective multiple chemical sensitivity (MCS) and matched control subjects, Clin Toxicol (Phila), 46 (2008) 443.
19. Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C & Goldenberg D L, The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the multicenter criteria committee, Arthritis Rheum, 33 (1990) 160.
20. Bradley L A, Pathophysiologic mechanisms of fibromyalgia and its related disorders,J Clin Psychiatry, 69 Suppl 2 (2008) 6.
21. Buskila D, Genetics of chronic pain states, Best Pract Res Clin Rheumatol, 21 (2007) 535.
22. Loeser J D, Butler S H, Chapman C R & Turk D C, Bonica's management of pain, 4supth/sup ed.: (Lippincott Williams and Wilkins, Philadelphia) 2008.
23. CDC-Centers for Disease Control and Prevention. http://www.cdc.gov/cfs/, 18.11.2008.
24. Lorusso L, Mikhaylova S V, Capelli E, Ferrari D, Ngonga G, K & Ricevuti G. Immunological aspects of chronic fatigue syndrome, Autoimmun Rev, 8 (2009) 287.
25. Moldofsky H, Fibromyalgia, sleep disorder and chronic fatigue syndrome, Ciba Found Symp, 173 (1993) 262.
26. Maes M, Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms, Curr Opin Psychiatry, 22 (2009) 75.
27. Mitchell R J, Osborne P B & Haubenreich J E, Dental amalgam restorations: Daily mercury dose and biocompatibility, J Long Term eff Med Implants, 15 (2005) 709.
28. Bates M N, Mercury amalgam dental fillings: An epidemiologic assessment, Int J Hyg Environ Health, 209 (2006) 309.
29. Heyer N J, Echeverria D, Farin F M & Woods J S, The association between serotonin transporter gene promoter polymorphism (5-HTTLPR), self-reported symptoms, and dental mercury exposure,J Toxicol Environ Health A, 71 (2008) 1318.
30. Reinhardt JW, Side effects: Mercury contribution to body burden from dental amalgam, Adv Dent Res, 6 (1992) 110.
31. Bergqvist U & Vogel E, Possible health implications of subjective symptoms and electromagnetic fields (National Institute for Working Life Solna), 1997, 170.
32. Ziskin M C, Electromagnetic hypersensitivity: A COMAR technical information statement, IEEE Eng Med Biol, 21 (2002) 173.
33. Levallois P, Hypersensitivity of human subjects to environmental electric and magnetic field exposure: A review of the literature, Environ Health Perspect, 110 Suppl 4 (2002) 613.
34. Havas M, Electromagnetic hypersensitivity: Biological effects of dirty electricity with emphasis on diabetes and multiple sclerosis, Electromagn Biol Med, 25 (2006) 259.
35. Portier C J & Wolfe M S, Assessment of health effects from exposure to power-line frequency electric and magnetic fields -NIEHS Working Group Report, Research Triangular Park (NC): National Institute of Environmental Health Sciences; 1998. NIH publications no 98-3981.
36. Hillert L, Berglind N, Arnetz B B & Bellander T, Prevalence of self-reported hypersensitivity to electric or magnetic fields in a population-based questionnaire survey. Scand J Work Environ Health, 28 (2002) 33.
37. Hillert L, Flato S, Georgellis A, Arnetz B B & Kolmodin-Hedman B, Environmental illness: Fatigue and cholinesterase activity in patients reporting hypersensitivity to electricity, Environ Res, 85 (2001) 200.
38. Flodin U, Seneby A & Tegenfeldt C, Provocation of electric hypersensitivity under everyday conditions, Scand J Work Environ Health, 26 (2000) 93.
39. Nieto-Hernandez R, James Rubin G, Cleare A J, Weinman J A & Wessely S, Can evidence change belief? Reported mobile phone sensitivity following individual feedback of an inability to discriminate active from sham signals, J Psychosom Res, 65 (2008) 453.
40. Levallois P, Hypersensitivity of human subjects to environmental electric and magnetic field exposure: A review of the literature, Environ Health Perspect, 110 Suppl 4 (2002) 613.
41. Lidén S, ''Sensitivity to electricity-a new environmental epidemic, Allergy, 51 (1996) 519.
42. Leitgeb N, Schröttner J & Böhm M. Does electromagnetic pollution cause illness? An inquiry among Austrian general practitioners, Wien Med Wochenschr, 155 (2005) 237.
43. Rubin G J, Munshi J D & Wessely S, Electromagnetic hypersensitivity: A systematic Review of provocation studies, Psychosom Med, 67 (2005) 224.
44. Black D W, Okiishi C & Schlosser S, A nine-year follow-up of people diagnosed with multiple chemical sensitivities, Psychosomatics, 41 (2000) 253.
45. Frick U, Rehm J & Eichhammer P, Risk perception, somatization, and self report of complaints related to electromagnetic fields-a randomized survey study, Int J Hyg Environ Health, 205 (2002) 353.
46. Ariga K, Ji Q, Hill J P, Kawazoe N & Chen G, Supramolecular approaches to biological therapy, Expert Opin Biol Ther, 9 (2009) 307.
47. Goldstone J V, Hamdoun A, Cole B J, Howard-Ashby M, Nebert D W & Scally M, The chemical defensome: Environmental sensing and response genes in the Strongylocentrotus purpuratus genome, Dev Biol, 300 (2006) 366.
48. Their R, Bruning T, Roos P H, Rihs H P, Golka K & Ko Y, Markers of genetic susceptibility in human environmental hygiene and toxicology: The role of selected CYP, NAT and GST genes, Int J Hyg Environ Health, 206 (2003) 149.
49. Korkina L & Pastore S, The role of redox regulation in the normal physiology and inflammatory diseases of skin, Front Biosci (Elite Ed), 1 (2009) 123.
50. Jaiswal A K, Nrf2 signaling in coordinated activation of antioxidant gene expression, Free Rad Biol Med 36 (2004) 1199.
51. Scandalios J G, Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses, Braz J Med Biol Res, 38 (2005) 995.
52. Wourmhoudt L W, Commandeur J N & Vermeulen N P, Genetic polymorphism of human N acetyltrasferase, cytochrom P450, glutathione-S-transferase, and epoxide hydrolases emzymes: Relevance to xenobiotic metabolism and toxicity, Crit Review Toxicol, 29 (1999) 59.
53. Meyer U A, Drugs in special patient groups: Clinical importance of genomics in drug effects, edited by Carruthers G S, Hoffmann B B, Melmon K L and Nieremberg D W, (McGraw Hill New York), 2000, 1179.
54. McKeown-Eyssen G, Baines C, Cole D E, Riley N, Tyndale R F & Marshall L, Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR, Int J Epidemiol, 33 (2004) 971.
55. Schnakenberg E, Fabig K R, Stanulla M, Strobl N, Lustig M & Fabig N, A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes, Environ Health, 6 (2007) 6.
56. Scordo M G, Caputi A P, DArrigo C, Fava G & Spina E, Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population, Pharmacol Res, 50 (2004) 195.
57. Skeith K J, Hussain M S, Coutts R T, Ramos-Remus C, Avina-Zubieta J A & Russell A S, Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia, Clin Rheumatol, 16 (1997) 291.
58. Eis D, Helm D, Mühlinghaus T, Birkner N, Dietel A & Eikmann T, The German multicentre study on multiple chemical sensitivity (MCS), Int J Hyg Environ Health, 211 (2008) 658.
59. Wiesmüller G A, Niggemann H, Weissbach W, Riley F, Maarouf Z & Dott W, Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): A case-control study, Int J Toxicol Environ Health A, 71 (2008) 786.
60. Whalen R & Boyer T D, Human glutathione S-transferases, Semin Liver Dis, 18 (1998) 345.
61. Strange R C & Fryer A A, The glutathione S-transferases: influence of polymorphism on cancer susceptibility, IARC Sci Publ, 148 (1999) 231.
62. Habdous M, Siest G, Herbeth B, Vincent-Viry M & Visvikis S, Glutathione S-transferases genetic polymorphisms and human diseases: Overview of epidemiological studies. Ann Biol Clin (Paris) 62 (2004) 15.
63. Bolt H M & Thier R, Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology, Curr Drug Metab, 7 (2006) 613.
64. Buskila D, Genetics of chronic pain states, Best Pract Res Clin Rheumatol, 21 (2007) 535.
65. Ben-Arie N, Khen M & Lancet D, Glutathione S-transferases in rat olfactory epithelium: Purification, molecular properties and odorant biotransformation, Biochem J, 292 (1993) 379.
66. Mannisto P T & Kaakkola S, Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors, Pharmacol Rev, 51 (1999) 593.
67. Tchivileva I E, Nackley A G, Qian L, Wentworth S, Conrad M & Diatchenko L B, Characterization of NF-kB-mediated inhibition of catechol-O-methyl transferase, Mol Pain, 5 (2009) 13.
68. Domschke K, Freitag C M, Kuhlenbäumer G, Schirmacher A, Sand P & Nyhuis P, Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women, Int J Neuropsychopharmacol, 7 (2004) 183.
69. Diatchenko L, Slade G D, Nackley A G, Bkalang K, Sigurdsson A & Belfer I, Genetic basis and individual variations in pain perception and the development of a chronic pain condition, Hum Mol Genet, 14 (2005) 135.
70. George S Z, Dover G C, Wallace M R, Sack B K, Herbstman D M & Aydog E, Biopsychosocial influence on exercise-induced delayed onset muscle soreness at the shoulder: Pain catastrophizing and catechol-o-methyltransferase (COMT) diplotype predict pain ratings. Clin J Pain, 24 (2008) 793.
71. Goertzel B N, Pennachin C, de Souza Coelho L, Gurbaxani B, Maloney E M & Jones J F, Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome, Pharmacogenomics, 7 (2006) 475.
72. Brierley C H & Burchell B, Human UDP-glucuronosyl transferases: Chemical defence, jaundice and gene therapy, Bioessays, 15 (1993) 749.
73. Berg M, Arnetz B B, Lidén S, Eneroth P & Kallner A Techno-stress. A psychophysiological study of employees with VDU-associated skin complaints, J Occup Med, 34 (1992) 698.
74. Baines C J, McKeown-Eyssen G E, Riley N, Cole DEC, Marshall L & Loescher B, Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures, Occup Med, 54 (2004) 408.
75. Lacoura M, Zunderb T, Schmidtkec K, Vaithd P & Scheidta C, Multiple chemical sensitivity syndrome (MCS) - suggestions for an extension of the US MCS-case definition, Int J Hyg Environ-Health, 208 (2005) 141.
76. Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C & Tokatlioglu B, Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction, Arch Med Res, 37 (2006) 133.
77. Ogata M, Wang D H & Ogino K, Mammalian acatalasemia: The perspectives of bioinformatics and genetic toxicology, Ada Med Okayama, 62 (2008) 345.
78. Terlecky S R, Koepke J I & Walton P A, Peroxisomes and aging, Biochim Biophys Ada, 1763 (2006) 1749.
79. Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A & Ricciotti D, Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome, Free Rad Biol Med, 29 (2000) 1252.
80. Richards R S, Wang L & Jelinek H, Erythrocyte oxidative damage in chronic fatigue syndrome, Arch Med Res, 38 (2007) 94.
81. Kennedy G, Spence V A, McLaren M, Hill A, Underwood C & Belch J J, Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms, Free Radic Biol Med, 39 (2005) 584.
82. Smirnova I V & Pall M L, Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients, Mol Cell Biochem, 248 (2003) 93.
83. Miwa K & Fujita M, Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome, Int J Cardiol, 136 (2009) 238.
84. Maes M, Mihaylova I, Kubera M & Bosmans E, Not in the mind but in the cell: Increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome, Neuro Endocrinol Lett, 28 (2007) 463.
85. Manuel y Keenoy B, Moorkens G, Vertommen J, Noe M, Nève J & De Leeuw I, Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: Effects of supplementation with magnesium, J Am CollNutr, 19 (2000) 374.
86. Logan A C & Wong C, Chronic fatigue syndrome: Oxidative stress and dietary modifications, Altern Med Rev, 6 (2001) 450.
87. Chung C P, Titova D, Oeser A, Randels M, Avalos I, Milne G L, Morrow J D & Stein C M, Oxidative stress in fibromyalgia and its relationship to symptoms, Clin Rheumatol, 28 (2009) 435.
88. Cordero M D, Moreno-Fernandez A M, deMiguel M, Bonal P, Campa F, Jimenez-Jimenez L M & Ruiz-Losada A, Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia, Clin Biochem, 42 (2009) 732.
89. Bagis S, Tamer L, Sahin G, Bilgin R, Guler H & Ercan B, Free radicals and antioxidants in primary fibromyalgia: An oxidative stress disorder? Rheumatol Int, 25 (2005) 188.
90. Pall M L, Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite, Med Hypotheses, 57 (2001) 139.
91. Pall M L, Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: Central role of N-methyl-D-aspartate receptors in the sensitivity mechanism, Environ Health Perspect, 111 (2003) 1461.
92. Simon G E, Daniell W, Stockbridge H, Claypoole K & Rosenstock L, Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study, Ann Intern Med, 119 (1993) 97.
93. Patarca R, Cytokines and chronic fatigue syndrome, Ann N Y AcadSci, 933 (2001) 185.
94. Dearman R J & Kimber I, Cytokine profiling and chemical allergy, Toxicol Appl Pharmacol, 185 (2002) 228.
95. Jammes Y, Steinberg J G, Delliaux S & Brégeon F, Chronic fatigue syndrome combines increased exercise induced oxidative stress and reduced cytokine and Hsp responses, J Intern Med, 266 (2004) 196.
96. Gibson P R, Elms A N & Ruding L A, Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity, Environ Health Perspect, 111 (2003) 1498.
97. Rappaport S M, Kim S, Lan Q, Vermeulen R, Waidyanatha S & Zhang L, Evidence that humans metabolize benzene via two pathways, Environ Health Perspect, 117 (2009) 946.